## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 1.35 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($304.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Gabelli Funds LLC Lowers Stock Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251209T094520 | Somewhat-Bullish | Relevance: 99%
-  Gabelli Funds LLC reduced its stake in UnitedHealth Group (NYSE:UNH) by 24.7% in the second quarter, selling 9,570 shares and ending with 29,170 shares valued at $9.1 million. Despite this reduction, other institutional investors either increased their holdings or initiated new positions. The company recently reported strong quarterly earnings, beating EPS estimates, and declared a quarterly dividend of $2.21 per share.

**2. Shepherd Financial Partners LLC Cuts Stake in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251207T113356 | Neutral | Relevance: 99%
-  Shepherd Financial Partners LLC significantly reduced its stake in UnitedHealth Group (NYSE:UNH) by 76.5% during the second quarter, selling over 4,400 shares and retaining 1,368 shares valued at $427,000. UnitedHealth Group reported strong Q2 earnings of $2.92 per share, exceeding expectations, with revenues up 12.2% year-over-year. The company also declared a quarterly dividend of $2.21 per share.

**3. UnitedHealth Group Stock (UNH) Opinions on DOJ Investigation and Analyst Upgrades**
- Source: Quiver Quantitative | 20251206T173400 | Neutral | Relevance: 98%
-  Discussions about UnitedHealth Group (UNH) on X are divided between investor concern over a DOJ investigation into Medicare billing practices and cautious optimism following recent analyst upgrades. The article details insider trading activity, UNH's Q3 2025 revenues, Congressional stock trading, hedge fund activity, government contracts awarded to UNH, and recent analyst ratings and price targets.

**4. Natixis Has $470.36 Million Stake in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251208T122946 | Bullish | Relevance: 98%
-  Natixis significantly increased its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 396.6% in the second quarter, now owning 1,507,698 shares valued at $470,357,000. Other institutional investors like Wellington Management Group, Geode Capital Management, and Norges Bank also adjusted their positions in the healthcare conglomerate. The article details UnitedHealth Group's recent financial performance, dividend announcement, and analyst ratings, with the stock currently having an average "Hold" rating.

**5. Stenger Family Office LLC Acquires Shares of 17,546 UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251206T131034 | Somewhat-Bullish | Relevance: 98%
-  Stenger Family Office LLC recently purchased 17,546 shares of UnitedHealth Group (UNH), valued at approximately $5.47 million, making it their 16th largest holding. UnitedHealth Group surpassed Q3 earnings estimates with an EPS of $2.92 and reported revenue of $113.16 billion, an increase of 12.2% year-over-year. The company also declared a quarterly dividend of $2.21 per share, offering an annualized yield of 2.7%.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 23 ($0.00M) |
| Sells | 1 ($0.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 10.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.35 suggests fair value with growth premium. Forward P/E 18.3x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $293.1B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.35 |
| Forward P/E | 18.3 |
| Current P/E | 19.8 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.2% to -2.3% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. MACD histogram positive (1.71), confirming momentum. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.27% (CS: 32) | Weak |
| RSI_14 | 45.2 | Neutral |
| MACD Histogram | 1.71 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.947x | Below |
| vs SMA200 | 0.896x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $323.62
- **Stop Loss:** $304.78 (5.8% risk)
- **Target:** $342.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $8,414.12
- **Portfolio %:** 8.41%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*